Dosing regimen for transdermal delivery of hormones comprising a variable treatment cycle and a variable rest interval.

A transdermal patch for use in auriculotherapy containing at least one active substance selected from caffeine, chocolate and glutamine for the modulation of neurotransmitters. The transdermal patch contains at least one ingredient selected from L-tyrosine, phenylalanine, 5-htp decarboxylase, 5-hydroxy-tryptophane, tryptophan, theobromine, anandamide, phenylethylamine, gamma hydroxybutyrate acid, gamma hydroxybutyric acid, GABA transaminase, theanine, taurine, homotaurine, melatonin, carnitine, acetyl-carnitine, S-Adenosylmethionine, N-acetyl L-cysteine, N-acetyl-transferase, phosphatidylserine, inositol, phosphatidylinositol, catalase, dopamine beta-hydroxylase, L-dopa descarboxylase, NADH, magnesium, zinc, manganese, chromium, copper, selenium, iron, calcium, lithium, calcium citrate, vitamin C, vitamin B, coenzyme Q10, omega-3, ashwagandha, Melissa oficinalis, Siberian ginseng, St. John's wort, valerian, Ginko biloba, Mucuna pruriens, turmeric, Rhodiola rosea and Bacopa monniera extracts.

Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

Dosing regimen for transdermal delivery of hormones comprising a monthly treatment cycle with a fixed treatment interval and a variable rest interval.

Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

The present invention relates to a solid pharmaceutical dosage form for abusable drug delivery with reduced illicit abuse potential. The dosage form is presented as a bioerodable transmucosal delivery device that includes an abusable drug and an antagonist to the abusable drug associated with an abuse-resistant matrix. The devices of the invention may be in the form of a layered film or a tablet. Upon application in a non-abusive manner, the device adheres to the mucosal surface, providing transmucosal drug delivery of the drug with minimal absorption of the antagonist into systemic circulation.

In one aspect, a method of treating smokeless tobacco addiction comprising administering to an individual in need thereof a pharmaceutical composition comprising nicotine, a therapeutically effective amount of cannabidiol, and a pharmaceutically acceptable vehicle therefor. In some aspects, the composition is administered transmucosally, such as in an oral dosage form or nasal spray. In other aspects, the composition is administered transdermally. In another aspect, a chewable gum contains nicotine in at least a base portion and cannabidiol in at least an outer portion thereof.

A medical delivery device is provided for delivering a medicinal substance into a user's body. An upper assembly includes a housing having a cavity configured for accommodating a needle. A lower assembly includes a receptacle member having an opening configured for accommodating insertion of the upper assembly, and a base member having an upper body and a recess formed on a top surface of the upper body for receiving the receptacle member. A base pad has an adhesive layer disposed on a lower surface of the pad, and being at least partially attached to a bottom side of the base member. The lower assembly is attached to a skin of the user using the base pad. As the upper assembly transitions from an upper position to a lower position relative to the lower assembly, the needle travels downwardly to penetrate the skin for facilitating administration of the medicinal substance.

To provide a phosphatidylcholine transdermal absorption preparation containing phosphatidylcholine in an adhesive layer. A phosphatidylcholine transdermal absorption preparation has a configuration in which an adhesive layer formed on at least one side of a support contains phosphatidylcholine, an adhesive component, and a lipophilic component, and thus the preparation becomes a patch-type transdermal absorption preparation which acts as a fat-decreasing agent which contains phosphatidylcholine and can exert an effect that local obesity such as subcutaneous fat is dissolved and fat is decreased by transdermal absorption of phosphatidylcholine as the preparation is pasted to the skin of a human body since phosphatidylcholine can be stably present in the adhesive layer and has an advantage due to the patch dosage form that the preparation can be fixed to the affected area and is more favorably handled as compared to liquid preparations and the like.

A microneedle patch is described that can be used for the sustained delivery of therapeutic agents into living tissue (e.g., skin). The polymer (gelatin methacryloyl (GelMA)) patch can adjust delivery rates based on the degree of crosslinking. The anticancer drug Doxorubicin (DOX) was loaded into GelMA microneedles using a molding fabrication technique. The GelMA microneedles efficiently penetrated the stratum corneum layer of a mouse cadaver skin. Mechanical properties and therapeutic agent release behavior of the GelMA microneedles can be adjusted by tuning the degree of crosslinking. The efficacy of the DOX released from the GelMA microneedles was tested and demonstrated the anticancer efficacy of the released drugs against melanoma cell line A375. Because GelMA is versatile material in engineering tissue scaffolds, GelMA microneedles can be used as a platform for the delivery of various types of therapeutic agents to tissue.